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A B S T R A C T
Blood coagulation factor XIII-A (FXIII-A), a member of the transglutaminase enzyme family, is best known for its
fibrin clot stabilizing function during blood coagulation. It possesses amine incorporating and protein cross-
linking transamidase activities, but it is also able to cleave the previously formed isopeptide bond by its iso-
peptidase activity. Our aim was to develop a protein-based assay for better characterization of FXIII-A iso-
peptidase activity. The first attempt applying the crosslinked D-dimer of fibrin as a substrate was not successful
because of poor reproducibility. Then, the principle of an earlier published anisotropy based activity assay was
adapted for the measurement of FXIII-A isopeptidase activity. After crosslinking the fluorescently labelled α2-
antiplasmin derived peptide and S100A4(GST) lysine donor protein, this protease-resistant γ-glutamyl-ε-lysine
isopeptide bond containing protein-peptide product was applied as a substrate for FXIII-A. Using this substrate
and detecting decreasing anisotropy, kinetic measurement of FXIII-A isopeptidase activity was achieved at high
sensitivity even in a complex biological sample and in the presence of inhibitor.
1. Introduction
Blood coagulation factor XIII-A (fibrin stabilizing factor, FXIII-A),
initially named after its discoverers as Laki-Lorand factor, is one of the
first described and best-known member of the transglutaminase enzyme
family. Firstly, its physiological function, stabilization of blood clots
making them urea insoluble, was recognized [1] and later it was re-
vealed that transglutaminase activity is responsible for fibrin cross-
linking [2,3]. FXIII-A also plays important roles in wound healing,
angiogenesis and maintaining pregnancy [4]. FXIII-A, as its best known
physiological function, catalyzes the Ca2+-dependent formation of γ-
glutamyl-ε-lysine crosslinks within fibrin clots after thrombin activation
during blood coagulation. In addition, it incorporates α2-antiplasmin,
one of the main inhibitors of fibrinolysis, into the blood clot, which, as a
result, becomes resistant against early fibrinolysis, suggesting the in-
volvement of FXIII-A in the regulation of the hemostatic balance be-
tween fibrin coagulation and fibrinolysis [5]. These indispensable
functions make FXIII-A inhibition a potential therapeutic target in an-
ticoagulation therapy, resulting in facilitated fibrinolysis without in-
creased bleeding tendency [6].
FXIII-A, similar to other transglutaminases, possesses various types
of calcium-dependent transglutaminase activities. The formation of
intermolecular γ-glutamyl-ε-lysine isopeptide bonds between fibrin
molecules is a typical example of FXIII-A transamidase activity. The
reaction mechanism has two main steps: in the first, an enzyme-sub-
strate intermediate is formed between a reactive glutamine residue and
the enzyme catalytic thiol group (Cys314; considering the removal of
the first Met) followed by ammonia release. In the second step, de-
pending on the presence of the other possible substrates, protein-pro-
tein crosslinking, amine incorporation occurs, or in the absence of eli-
gible amine donor substrate, deamidation can occur [7,8]. Several
biogenic and synthetic primary amine molecules, can be incorporated
by transamidation into glutamine residues of proteins which could be
either responsible for biological functions or useful as a research tool
inhibiting transglutaminase mediated crosslink formation [9,10]. Re-
cently, it was confirmed, that FXIII-A also has deamidation activity with
peptide substrates when an amine-donor substrate is not present [11].
FXIII-A, similar to tissue transglutaminase (transglutaminase 2,
TG2) [12], has another type of hydrolase activity: it can reverse its
transamidase activity and cleave the previously formed isopeptide
bond. Ichinose and Aoki demonstrated that FXIII-A is able to crosslink
α2-antiplasmin to, then release it from fibrinogen [13] and some years
later they also demonstrated the release of α2-antiplasmin from plasma
fibrin clot [14]. The biochemical details of this isopeptidase activity
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were described first by Lorand's laboratory using several synthetic,
fluorescently labelled peptides which were crosslinked with a small
quencher in an isopeptide bond mimicking fashion. The isopeptidase
activity of guinea pig and human TG2 and human FXIII-A were tested
kinetically by the increase of fluorescent signal [15]. In the same year,
Loewy et al. also published another method to detect isopeptidase ac-
tivity, applying radioisotope labelling [16].
Measuring the isopeptidase activity of FXIII-A could provide a good
possibility for accurate, highly sensitive determination of FXIII-A ac-
tivity in plasma, particularly in the case of FXIII-A deficient patients.
Zedira Gmbh. (Darmstadt, Germany) has developed a sensitive, com-
mercial, α2-antiplasmin derived peptide-based isopeptidase substrate
[17]. The unique advantage of detecting isopeptidase activity is that
there is no alternative, parallel reaction and the substrate conversion
always proceeds in one direction because in the product the remaining
glutamate does not react again with the enzyme. However, transglu-
taminases frequently act on protein substrates resulting in different
reaction kinetics, which could not be predicted using peptide and small
amine substrates as, for example, used in the Zedira isopeptidase assay.
In addition, previously, we developed TG2 mutants which demonstrate
enhanced isopeptidase activity on peptide substrates using the Zedira
assay, but decreased activity in the case of protein-peptide based sub-
strates, suggesting the need for protein-peptide based kinetic iso-
peptidase activity assays in the field [12].
In the current study, first, we made an attempt to apply a newly
developed commercial monoclonal antibody (Zedira) against the cross-
linked fibrin degradation product D-dimer for monitoring at the protein
level the change of isopeptide bond content as a result of FXIII-A ac-
tivity. Then, we successfully adapted our previously developed protein-
peptide substrate based method which follows anisotropy change
during the cleavage of isopeptide bond between a protein
(S100A4(GST)) and a fluorescently labelled peptide substrate
(FLpepPI2) to characterize FXIII-A isopeptidase activity.
2. Materials and methods
2.1. Materials
All materials were purchased from Sigma (St Louis, MO, USA) unless
otherwise indicated. The FLpepT26 (5FAM-HQSYVDPWMLDH-NH2),
FLpepPI2 (5FAM-NQEQVSPLTLLK-NH2) peptides were obtained from
GenScript (Piscataway, NJ, USA). The FLpepT26 and FLpepPI2 peptides
have a molecular mass of 1885 and 1727 Da, respectively, but generally
appear in the 15% SDS-polyacrilamide gel as 14 or 12 kDa diffuse
bands, respectively (Fig. 2D). GPRP peptide, an inhibitor of fibrin ag-
gregation was purchased from Cayman Europe (Tallinn, Estonia). Re-
combinant commercial FXIII-A produced in insect cells (T027), fibrin
degradation products (FDP; F012), cross-linked fibrin degradation
products (xFDP; F011), DD-XLink-mab (A076), FXIII-Assay substance
(A101) and ZED1301 site specific irreversible inhibitor of FXIII-A
(A108) were produced by Zedira (Darmstadt, Germany).
2.2. Expression and purification of proteins
For isopeptidase substrate production, N-terminal glutathione S-
transferase (GST)-tagged S100A4, a member of the S100 small, Ca2+
binding EF-hand containing protein family (pETARA-S100A4; Uniprot
code: P26447; Mw: 39,559 Da), was expressed in E. coli Rosetta 2(DE3),
an E. coli BL21 derivative strain containing a vector, expressing 7 barely
present eukaryotic tRNAs in bacterial cells (Novagen, Darmstadt,
Germany), exactly as described in the earlier published method [12].
Human recombinant TG2 was expressed and purified also based on the
earlier published method [12].
2.3. Large scale production of the crosslinked FLpepT26-S100A4(GST),
FLpepPI2-S100A4(GST)
5 μM FLpepT26 or FLpepPI2 and 12.8 μM S100A4(GST) were in-
cubated at 37 °C for 90 min in the presence of 5 nM TG2, 5 mM Ca2+ in
20 mM HEPES reaction buffer, pH 8.0 containing 150 mM NaCl, 5 mM
dithiothreitol (DTT), 0.01% Tween 20. The reaction was stopped by the
addition of 10 mM EDTA (final concentration) and FLpepT26-
S100A4(GST) or FLpepPI2-S100A4(GST) with unmodified
S100A4(GST) were separated from the free, unbound FLpepT26 or
FLpepPI2 peptide by a centrifugal concentrator filter (Amicon ultra,
10 kDa, Millipore, Billerica, MA, USA). Then, the buffer was replaced by
20 mM MOPS buffer, pH 6.8, containing 0.5 mM EDTA, 150 mM NaCl,
5 mM DTT, 0.01% Tween-20 due to the slightly acidic pH preference of
the isopeptidase activity [12]. Due to the co-purification of the cross-
linked isopeptide bond containing products and S100A4(GST) their
ratios were calculated based on the total protein concentration (de-
termined by Bio-Rad Protein Assay) and its fluorescein content (ab-
sorption at 493 nm) using 79600 M−1 cm−1 as the molar extinction
coefficient for fluorescein. Under optimized conditions the FLpepPI2-
S100A4(GST) content was approximately 7% on average in the reaction
product, meaning that in the purified mixture 5 μg of FLpepPI2-
S100A4(GST) and S100A4(GST) corresponds to 259.5 nM FLpepPI2-
S100A4(GST) in 35 μl of the isopeptidase assay mixture.
To exclude the potential effect of remaining TG2 in the substrate
used for the formation of isopeptide bond, and uncrosslinked
S100A4(GST), after separation of free peptide substrates (FLpepT26/
PI2), control experiments were performed. On the one hand, in the
absence of any freshly added enzyme into the reaction mixture, con-
taining 5 mM CaCl2, we were unable to detect any fluorescence po-
larization change compared to the EDTA and iodoacetamide control,
suggesting that there is no remaining TG2 activity in the substrate. On
Fig. 1. An attempt to detect reversibility
of fibrin crosslinking by FXIII-A at the
protein level using a crosslinked fibrin
degradation product specific mono-
clonal antibody.
DD-Xlink-mab (Zedira) recognizes the iso-
peptide bond containing fibrin degradation
products. Based on the manufacturer web-
page the band(s) at 72 kDa represents γ-γ or
γ′-γ fibrin dimers while there is no in-
formation concerning the other band
around 40 kDa. After a 2 h incubation, the
effect of activated FXIII-A on the level of
isopeptide bond in the crosslinked fibrin
degradation products was visualized on re-
presentative Western blot images. The
upper band intensities were calculated by
ImageJ and the values are given as a percentage of the untreated controls. Representative Western blots are presented of more than 3 independent experiments.
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the other hand, 5 μg of the uncrosslinked S100A4(GST) demonstrated
only a slight (5.5%) inhibitory effect on FXIII-A isopeptidase activity
using Zedira A101 substrate based on the manufacturer instructions
(data not shown).
2.4. Preparation of samples after kinetic reactions for SDS-PAGE analysis
The activity assays were stopped by adding 6x denaturation buffer
(300 mM Tris-HCl, pH 6.8, 0.43 M β-mercaptoethanol, 12% (m/v) SDS,
20% (v/v) glycerol, 0.06% (m/v) bromophenol blue) and the samples
were boiled for 10 min. SDS-PAGE was performed using 15% Tris-
Glycine gels. The fluorescence was detected immediately by means of a
PharosFX Plus Molecular Imager (Ex/Em: 488/530 nm; Bio-Rad).
2.5. Kinetic transamidase activity measurement
A fluorescence polarization assay, originally published by Kenniston
and co-workers [18], was used to detect the crosslinking activity of
transglutaminases based on our earlier publication [12] with some
modifications. Briefly, 5 nM TG2 or FXIII-A enzyme and 100 nM
FLpepT26 or FLpepPI2 peptide were incubated with 5 μM S100A4(GST)
in 20 mM HEPES buffer, pH 7.5, containing 150 mM NaCl, 5 mM DTT,
0.01% Tween-20 in the presence of 10 mM EDTA and 2 mM iodoace-
tamide (IA) or 5 mM Ca2+ as a negative control or test reaction, re-
spectively. The final volume of the reaction mixture was 35 μl in Un-
treated Polystyrene Black Microplates (Nunc, Thermo Scientific,
Denmark; catalog# 262260) and contained 500 mU thrombin when
FXIII-A activity was tested. The reaction was started by the addition of
enzyme solution and performed at 37 °C, measuring the change in
fluorescence polarization (FP) value by a Synergy H1 microplate reader
(GreenFP filter cube, Ex: 485 nm, Em: 528 nm; Gain: 75; BioTek, Wi-
nooski, VT, USA). The reaction rates were calculated in terms of ani-
sotropy per minute from the initial slopes of the kinetic curves in the
case of TG2, while in the case of FXIII-A after an approximately 4 min
lag period.
2.6. Kinetic isopeptidase activity measurement
In 35 μl reaction volume on 384-well Untreated Polystyrene Black
Microplates, 380 nM of the FLpepT26-S100A4(GST) or 259.5 nM of the
FLpepPI2-S100A4(GST) crosslinked substrates (5 μg of FLpepT26-
S100A4(GST) or FLpepPI2-S100A4(GST) and S100A4(GST)) were used
in 20 mM MOPS, pH 6.8, reaction buffer containing 100 mM NaCl,
5 mM CaCl2, 6 mM glycine methyl ester, 3 mM DTT, 0.1%
Polyethylene-glycol 8000 and various concentration of recombinant
human TG2 or FXIII-A. In the case of FXIII-A the reaction mixture
contained 500 mU human thrombin. Normal human plasma samples
were analyzed in the presence of 2 mM GPRP peptide and 5 mg/ml
polybrene. The reaction was started by the addition of enzyme solution
and performed at 37 °C, measuring the change in fluorescence polar-
ization (FP) value by means of a Synergy H1 microplate reader
(GreenFP filter cube; Gain: 63). The negative control contained 10 mM
EDTA and 2 mM iodoacetamide to inhibit transglutaminase activity.
The reaction rates were calculated in terms of anisotropy per minutes
from the initial slopes of the kinetic curves in the case of TG2, while in
the case of FXIII-A after an approximately 4 min lag period.
2.7. Reaction conditions and western blot to test the specificity and
applicability of DD-Xlink-mab for detection of isopeptide bond
Crosslinked fibrin degradation product (xFDP) and fibrin degrada-
tion product (FDP) were incubated with or without recombinant human
FXIII-A in the presence of 500 mU thrombin, 10 mM CaCl2 in 20 mM
MOPS reaction buffer, pH 6.8, containing 100 mM NaCl, 5 mM CaCl2,
6 mM glycine methyl ester, 3 mM DTT, 0.1% Polyethylene-glycol 8000.
The reaction mixtures were incubated at 37 °C for 2 h. Then, the re-
actions were stopped by the addition of 6x denaturation buffer and the
samples were boiled for 10 min. SDS-PAGE was performed using 10%
Tris-Glycine gels, which was followed by a blotting step performed with
a Bio-Rad Trans-blot SD Semi-dry Transfer Cell. For blocking, the
membrane was incubated in 5% (m/v) low-fat milk powder in TTBS
(0.1% (v/v) Tween-20 in TBS) for 1 h at room temperature or overnight
at 4 °C. DD-XLink-mab primary (Zedira; 1/7500) and Goat anti-mouse
IgG(H + L) (1/10000; Advansta, San Jose, CA, USA) secondary anti-
bodies were diluted in 0.5% low-fat milk powder containing TTBS.
Finally, WesternBright ECL HRP substrate (Advansta) was used for
signal development.
2.8. Data analysis
Data analysis, curve fitting, kinetic calculations and statistics were
performed using GraphPad Prism 6 and 8 software (Graphpad Software
Inc. La Jolla, CA, USA) using the appropriate incorporated equations
and tools mentioned where it is appropriate.
Fig. 2. Incorporation of FLpepPI2 pep-
tide into S100A4 protein catalyzed by
FXIII-A applied for kinetic detection of
FXIII-A transamidase activity at the pro-
tein-peptide level.
The fluorescence polarization change was
followed using BioTek Synergy H1 Green FP
filter cube (A; representative picture, Ex/
Em: 485/525; mirror: 510 nm) during TG2
or FXIII-A (5 nM) catalyzed transamidase
reaction in the presence of 100 nM
FLpepT26 or FLpepPI2 and 5 μM
S100A4(GST) substrates. The reaction rates
(B) were calculated based on the first ap-
proximately linear range of the kinetic
curves or after a short lag period in the case
of FXIII-A. Data are presented as the
mean±SD from two independent experi-
ments performed in triplicate. To visualize
the crosslinked product, after denaturation,
the reaction mixtures were subjected to
15% SDS-PAGE and proteins were immediately detected by a PharosFX Plus Molecular Imager (D). The asterisk marks the crosslinked protein-peptide product.
Finally, the gel was Coomassie stained to compare the amount of S100A4(GST) proteins in the loaded samples (C, representative gel images).
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3. Results and discussion
3.1. An attempt to detect isopeptidase activity of FXIII-A on fibrin D-dimer
using a monoclonal antibody and western blotting
The role of FXIII-A in blood coagulation and fibrinolysis is a good
example of how transglutaminases are involved in essential biological
processes by protein crosslinking and later by the cleavage of the pre-
viously formed covalent bond. The incorporation of α2-antiplasmin and
later its release from the clot is already known. However, there is no
evidence as to whether FXIII-A can cleave the previously formed iso-
peptide bond between fibrin subunits. The FXIII-A catalyzed covalent
crosslink between the γ-γ subunits of fibrin/fibrinogen (D-dimer) can be
recognized using a recently developed monoclonal antibody by Zedira
Gmbh. for differentiation between fibrin degradation products which
contain or do not contain an isopeptide bond (Fig. 1). Circulating D-
dimer, containing covalent crosslinks between fibrin subunits, is a good
marker of blood coagulation and an indicator of sufficient activation
and level of FXIII-A.
We thought that the application of this monoclonal antibody could
also help in the protein-based detection of FXIII-A isopeptidase activity.
We incubated the cross-linked fibrin degradation products (xFDP and D-
dimer) in the presence of activated FXIII-A. To facilitate isopeptidase
activity, glycine methyl ester and pH 6.8 was applied. After 2 h in-
cubation, by evaluating the integrated pixel densities on the film using
ImageJ, we have observed regularly, but not consistently, an apparent
10–20% decrease in the level of the antibody recognized xFDP band
(upper band on Fig. 1 was analyzed). Based on several repetitions of the
experiment, sometimes with extended incubation time, we can con-
clude that this application of the antibody combined with Western blot
is not applicable to accurately monitor the level of isopeptide bond
between the fibrin subunits. The reason could be technical difficulties
associated with the sample loading, electrophoresis, blotting method, or
during the incubation period, additional crosslinking can cause a still
undetectable shift in the size of the D-dimer influencing the accurate
determination of the isopeptide bond. But, the antibody-based detec-
tion of crosslinked fibrin degradation product could still be a good
qualitative marker of FXIII-A transamidase activity during blood coa-
gulation.
Probably due to a still unknown steric regulation, FXIII-A does not
cleave the previously formed isopeptide bond between fibrin molecules.
After fibrinolytic and proteolytic degradation of the blood clot at pep-
tide bonds, ε-(γ-glutamyl)lysine dipeptide remains in the circulation
due to the resistance of the isopeptide bond to such cleavage.
Eventually, however, the isopeptide bond is cleaved by cyclo-
transferases which are significantly expressed in the intestine and
kidney [19,20]. Therefore, a higher level of ε-(γ-glutamyl)lysine di-
peptide in the serum is a good marker of blood coagulation events and
over activation of transglutaminases in other diseases [21,22].
In the literature, an enzyme named destabilase isolated from med-
icinal leech saliva was reported to accelerate fibrinolysis through hy-
drolyzing FXIII-A formed crosslinks [23]. Baskova and co-workers de-
monstrated that this enzyme is able to enhance the lysis of blood clots
by hydrolyzing the isopeptide bond. We also cloned, expressed and
purified by one-step affinity chromatography the destabilase 3 isoform
[24]. After incubation of xFDP and D-dimer with the recombinant de-
stabilase 3 the level of DD-Xlink-mab recognized xFDP was lower than
that in the reaction mixture lacking enzyme (approximately 20% de-
crease based on integrated optical density analysis; data not shown).
3.2. Protein-peptide based method for FXIII-A transamidase activity
measurement
In order to develop real-time monitoring methods for character-
ization of FXIII-A activities at the protein-peptide level, we examined
whether FXIII-A accepts as substrates the S100A4(GST) recombinant
protein and FLpepT26 or FLpepPI2 fluorescently labelled dodecapep-
tides. Earlier, we had improved a fluorescence anisotropy based assay
which applied bovine serum albumin (BSA) and FLpepT26 (fluores-
cently labelled T26 peptide) for monitoring TG2 transamidase activity
[18]. BSA was replaced by S100A4(GST) which is an excellent substrate
for TG2. It has only one transglutaminase reactive lysine residue
(Lys100 in S100A4) with good accessibility on its C-terminal [25].
Peptide T26 (HQSYVDPWMLDH) is a phage display selected TG2 spe-
cific artificial dodecapeptide containing only one reactive glutamine
residue [26]. Peptide PI2 (NQEQVSPLTLLK) is also a dodecapeptide but
derived from the N-terminal sequence of α2-antiplasmin and it is an
excellent substrate for both FXIII-A and TG2 [27]. In the current assay,
crosslinking transamidase activity was followed by the measurement of
exponentially increasing fluorescent anisotropy (Fig. 2A). Then the
activity values were calculated based on the linear regression of the first
phase of the increasing fluorescent polarization (R-squared values were
close to 1; Fig. 2B). In the presence of FLpepT26 and S100A4(GST)
FXIII-A did not generate an easily detectable anisotropy change. But,
after the tests were completed, SDS-PAGE analysis of the reaction
mixture demonstrated the appearance of a faint fluorescent band at
approximately 42 kDa in the case of both enzymes. This confirms that
FLpepT26 peptide is incorporated into S100A4(GST) by both enzymes,
but in the case of FXIII-A to a very low extent (Fig. 2D, loading control
on Fig. 2C). T26 peptide was developed as a TG2 preferred peptide
substrate and it has only low reactivity with FXIII-A, explaining the
undetectable kinetic signal [26]. Then FLpepT26 peptide was replaced
by FLpepPI2 and we have detected an increase of the fluorescent po-
larization in the presence of active FXIII-A and lower reactivity with
TG2 (Fig. 2A). The SDS-PAGE analysis (Fig. 2D) confirmed that TG2 can
accept FLpepPI2 peptide as a substrate [27,28] and incorporate it into
S100A4(GST), but to a lower extent than FXIII-A.
The application of a natural lysine donor FXIII-A substrate, fi-
brinogen, was also considered in the assay development. But fibrinogen
has several transglutaminase reactive residues, both lysine and gluta-
mine, and has a strong tendency to aggregate. Crosslinking of
S100A4(GST) and fluorescently labelled dodecapeptides generates an
easily detectable anisotropy change (more than 25 mr; Fig. 2A) de-
monstrating that selection of substrate molecules which have only one
reactive residue in an exposed position and having similar size to
S100A4(GST) could lead to the development of a widely applicable
kinetic activity test for each transglutaminase family member. Earlier,
Yamada and Meguro published for FXIII-A activity measurement a
fluorescence anisotropy based activity assay using casein and mono-
dansyl cadaverine as substrates [29]. Later, Hauser and co-workers
analyzed in detail the possibilities, advantages and disadvantages of
monitoring fluorescence anisotropy changes caused by the increase of
size and paralleling the change of rotation parameters of fluorescently
labelled substrates as a consequence of the transamidase activity [30].
They suggested the application of rhodamine B fluorophore instead of
fluorescein due to its favorable spectral property. They also concluded
that a fluorescence anisotropy based assay is a convenient and simple
way to follow transglutaminase activity, which correlates with the
amount of the enzyme. Our experiments using different peptide sub-
strates raise the possibility of developing isoenzyme specific protein-
peptide based assays to measure the activity of various co-expressed
transglutaminases from the same biological samples.
Real-time monitoring of FLpepPI2 and S100A4(GST) crosslinking
could serve as a protein-peptide based kinetic FXIII-A assay. However,
under this assay condition transamidation, deamidation and isopeptide
cleavage can occur simultaneously, which could decrease the assay
precision. The incorporation of α2-antiplasmin by FXIII-A into Aα-
chain of fibrinogen molecules reaches an equilibrium level in which
steric hindrance and the parallel isopeptide cleavage could be also in-
volved. These features could influence the determination of FXIII-A
level in a biological sample, but monitoring isopeptidase activity
probably would avoid these concerns.
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3.3. Adaptation of a protein-peptide based kinetic isopeptidase assay for
FXIII-A (by replacement of the TG2 specific peptide component)
Previously, we described a protein-peptide based isopeptidase ac-
tivity assay to characterize TG2 isopeptidase activity [12]. We hy-
pothesized that if the crosslinking of a protein and labelled peptide is
detectable following the change of fluorescent anisotropy, the cleavage
of the isopeptide bonds could be also detectable in the same way, but
with reverse signal direction. In addition, the Lys100 in S100A4 may be
in a unique steric position, making it a good substrate for other trans-
glutaminases. Since there is no detailed study concerning the specificity
of FXIII-A isopeptidase activity, first, we tested FLpepT26-S100A4(GST)
as a potential isopeptidase substrate (Fig. 3A). In agreement with our
expectation, FXIII-A did not cleave the crosslink in FLpepT26-
S100A4(GST) which was also confirmed by SDS-PAGE analysis de-
monstrating similar fluorescence band intensity of isopeptide bond
containing substrate around 42 kDa in the control and in the presence
of FXIII-A in the reaction mixture (Fig. 3D; loading control on Fig. 3C).
As a next step, the peptide part of the crosslinked protein-peptide
substrate, FLpepT26 was replaced by FLpepPI2 peptide. However,
FXIII-A accepts FLpepPI2 as a substrate with a higher velocity and in-
corporation ratio than TG2. Therefore, to prevent any unwanted effect
of remaining FXIII-A later, S100A4(GST) and FLpepPI2 were cross-
linked by TG2 to prepare the optimal substrate for the final assay
conditions. After a short 4 min lag period (activation of FXIII-A), the
anisotropy change followed an exponential decay. Using linear regres-
sion based on this approximately linear phase (between 4 and 14 min)
of the decrease, reaction rates were calculated and are presented in
Fig. 3B after subtracting the blank values. Indeed, the FLpepPI2-
S100A4(GST) served as a substrate providing sufficient signal to
monitor kinetically FXIII-A isopeptidase activity at the protein-peptide
level (Fig. 3A and B). The cleavage of the isopeptide bond was also
demonstrated by SDS-PAGE, showing a decreased amount of fluores-
cence labelled crosslinked product (around 42 kDa) and a stronger
peptide band compared to the control (around 12 kDa; Fig. 3D).
This confirms our hypothesis that the replacement of the peptide
part in the substrate molecule, can produce a protein-peptide based
substrate for other transglutaminase family members. Sugimura et al.
published an artificial, phage display selected dodecapeptide, F11
peptide [26], which also serves as a better substrate of FXIII-A than of
TG2. The application of F11 peptide in the crosslinked substrate could
theoretically further improve the specificity of this assay.
3.4. Sensitivity, linearity, detection limit of the protein-peptide based kinetic
isopeptidase assay for FXIII-A
In order to test the potential applications of the protein-peptide
based FXIII-A kinetic isopeptidase assay, first, the effect of increasing
FLpepPI2-S100A4(GST) concentration on the reaction rate was mea-
sured in the presence of 150 nM FXIII-A. The activity values followed
saturation kinetics, and a curve was fitted using the Michaelis-Menten
equation (Fig. 4A, coefficient of determination: R2 = 0.928). The ac-
tivity attained a plateau phase and Km and Vmax parameters were cal-
culated as 4.10 ± 0.76 nM and 54.92 ± 1.7 mr/min/nM FXIII-A,
respectively, using GraphPad Prism.
This Km is extremely low compared to other published values for
human FXIII-A substrates. For example, Oertel and co-workers [17]
published a fluorometric method which was also developed based on
the isopeptidase activity of FXIII-A; the Km value for their modified
peptide substrate was 19.8 ± 2.8 μM. In the case of the widely applied
transglutaminase assay when the released ammonia was followed from
the α2-antiplasmin derived dodecapeptide (PI2) the Km(app) was
530 μM [27]. When TG2 transamidase activity was measured by fol-
lowing the fluorescence anisotropy change using DMC and fluores-
cently labelled cadaverine substrates the apparent Km value for DMC
was in the subnanomolar range and for cadaverine analogues even
lower [30]. Due to the same detection method, it is likely that in our
assay complex interactions between the concentration of fluorophore
labelled substrate molecules and fluorescence anisotropy (for short re-
view of this effect see Ref. [30]) are responsible for the observed
maximal reaction rate. Under the current conditions, the low Km value
cannot be explained solely on the basis of kinetics. One of the simplest
explanation could be that protein-peptide based substrates have a
higher affinity for the enzyme than small peptides or amines, due to a
higher number of potential interacting residues between them. Con-
sidering the explicit meaning of Km, either the substrate affinity is high
towards the enzyme or the conversion rate of the substrate is low, or
both together can result in a low Km value.
As a next step, to obtain data on the linearity and sensitivity of the
assay we measured the correlation between FXIII-A concentration and
activities in the presence of 259.5 nM FLpepPI2-S100A4(GST) substrate
(Fig. 4B). When FXIII-A activity was measured up to 150 nM con-
centration, the Pearson correlation coefficient was 0.9387 with
0.8811 R-square value, suggesting a strong, but not exactly linear
correlation between FXIII-A concentration and activity in the whole
examined concentration range. The lowest measurable FXIII-A con-
centration was 1.0 nM. When the data were reanalyzed in a smaller, up
Fig. 3. Cleavage of FLpepPI2-
S100A4(GST) protein-peptide based sub-
strate provides the possibility of kineti-
cally following FXIII-A isopeptidase ac-
tivity.
Fluorescence polarization change (A)
during isopeptidase activity of 150 nM TG2
or FXIII-A enzyme in the case of 380 nM
FLpepT26-S100A4(GST) or 259.9 nM
FlpepPI2-S100A4(GST) substrates (5 μg
mixture of S100A4(GST)-FLpepT26/PI2 and
S100A4(GST)) was followed by BioTek
Synergy H1 Green FP filter cube (Ex/Em:
485/525; mirror: 510 nm). The reaction
rates (B) were calculated based on the first
approximately linear range of the kinetic
curves. Data are presented after control
subtraction as the mean±SD from two in-
dependent experiments performed in tripli-
cate. To visualize the cleavage, after dena-
turation, the reaction mixtures were separated by 15% SDS-PAGE and proteins were immediately detected by a PharosFX Plus Molecular Imager (D). The asterisk
marks the crosslinked protein-peptide substrate. Finally, the gel was Coomassie stained to visualize the loaded S100A4(GST) (C, representative images).
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to 15 nM FXIII-A concentration range (Fig. 4B inset), the correlation
coefficient was 0.9907 with 0.9816 R-square value. For plasma FXIII-A
activity measurement, the sample is usually mixed with the reaction
mixture in a 1:10 ratio. The mean of physiological FXIII-A concentra-
tion is approximately 50 nM [17] and the reference interval is between
69 and 143% [27], which by taking into account the 10 times dilution,
overlaps with the linear range of our protein-peptide based assay,
suggesting that it could determine the physiological FXIII-A level in the
human plasma. This FXIII-A concentration range is smaller than that in
the case of the Hauser and co-workers [30] published fluorescence
anisotropy assay measuring TG2 activity, where the optimal enzyme
concentration range was 0.5–5 μg/ml, which corresponds to approxi-
mately 5–63 nM enzyme (FXIII-A) in our assay.
In order to further evaluate the applicability of the assay, normal
human plasma was added at a 1:10 dilution to the reaction buffer which
contained a various concentration of recombinant human FXIII-A. To
obtain an appropriate blank value in the presence of plasma, the
transglutaminase activity of endogenous FXIII-A was inhibited by che-
lating Ca2+ using 10 mM EDTA and adding iodoacetamide as an –SH
group reactive alkylating agent (Fig. 4C). The reaction rate of the
normal plasma was 1.22 ± 0.18 mr/min without recombinant FXIII-A
addition, which was subtracted from the activity values before plotting.
Interestingly, in the presence of normal human plasma, the corrected
activities resulted in better correlation parameters but lower activity
values. Up to 50 nM recombinant FXIII-A concentration, the Pearson
correlation coefficient was 0.9950, with 0.9901 R-square value and the
coefficient of determination for the fitted line was 0.9422. The smallest
clearly measurable FXIII-A concentration (sensitivity) was at 5 nM re-
combinant FXIII-A. Below this concentration, the differentiation from
the blank anisotropy change value was not possible. The diagnostic test
reactions usually contain the plasma at a 1 to 10 dilution. This corre-
sponds to 5 nM FXIII-A in the assay conditions when FXIII-A level is
physiological in the plasma [17], suggesting that in the examined ex-
perimental setting, the diagnostic application of the assay is limited.
In bleeding disorders, the accurate determination of clotting factor
levels is essential for the diagnosis of the disease and for checking the
efficiency of factor complementation treatment. Measuring FXIII-A ac-
tivity provides an excellent tool for the identification of FXIII-A defi-
ciency [31]. Sensitive methods have been developed to determine FXIII-
A transamidase activity using fluorescently, radioisotope or biotin la-
belled amines, but their application is difficult and time-consuming,
due to technical difficulties and safety issues [31]. Microtiter plate
based methods provide good reproducibility when using various sub-
strates for coating the plate and various biotin labelled substrates for
Fig. 4. Kinetic parameters of the FLpepPI2-S100A4(GST) protein-peptide based substrate and sensitivity, linearity and potential applications of the newly
developed FXIII-A isopeptidase activity assay.
Determination of the Michaelis constant in the presence of 150 nM FXIII-A (A) and the correlation between FXIII-A concentration and activity in the absence (B) and
presence of normal human plasma (C). The inset highlights the correlation around the physiological FXIII-A concentration. Dose-dependent inhibitory effect of
iodoacetamide (IA, solid line) and ZED1301 FXIII-A specific inhibitor (dashed line) on the isopeptidase activity of 50 nM FXIII-A (D). The reaction rates were
calculated based on the approximately linear range of the kinetic curves. Data are presented as mean± SD from two independent experiments performed in
triplicate.
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the detection of their incorporation, but these methods are still time-
consuming and relatively laboratory extensive [32,33]. In 1971 Lorand
et al. published a continuous fluorescent method based on the in-
corporation of dansyl-cadaverine into dimethylated casein, which is
capable of automated determination of FXIII-A activity in plasma [34].
Today, there are two widely used commercial assays for screening
FXIII-A level (Berichrom and Technochrom), and both depend on the
first catalytic step of the transamidase reaction, which is followed by
ammonia release [35,36]. This feature makes possible the real kinetic
monitoring of the reaction rate during a short period. The advantage of
these assays is that they detect a change which is relatively independent
of the second substrate and measures the potential parallel deamidation
activity of FXIII-A [11,31]. Unfortunately, using our method, the de-
tection and differentiation of the most severe cases of FXIII-A deficiency
where the enzyme level is less than 5% of the normal value leading to
severe bleeding disorders, is not possible. However, the coupled kinetic
test that detects ammonia release is able to differentiate between this
severe form of FXIII-A deficiency and the mild FXIII-A deficiency, which
causes mild or not observable bleeding when FXIII-A activity in the
plasma is between 5 and 30% of the normal value [37].
The optimization of the assay for a simple microfluidic platform
could be the subject of the next study. The further purification of the
substrate from the unmodified S100A4(GST) and application of F11
peptide instead of PI2 could also improve this method.
As inhibition of FXIII-A is a therapeutic goal to prevent unwanted
blood clot stabilization, the application of a protein-peptide based assay
for drug testing would be useful because in vivo FXIII-A acts on protein
substrates. The effect of iodoacetamide (IA), a general transglutaminase
inhibitor and ZED1301, a FXIII-A specific peptidomimetic inhibitor
were tested in the anisotropy based FXIII-A assay (Fig. 4D). In the
presence of IA and ZED1301 dose-dependent inhibitions were detected
with 1.89 ± 0.29 μM and 268 ± 56 nM IC50 values, respectively.
However, the IC50 values are not comparable between different test
conditions, but this iodoacetamide concentration is relatively high in
the case of 50 nM FXIII-A concentration. We speculate that this higher
iodoacetamide concentration correlates with the potentially higher af-
finity of the protein-peptide substrates than a small substrate molecule,
suggesting that the efficiency of other FXIII-A inhibitors in vivo could
be significantly different from the values generated in such assays using
small substrate molecules. Application of a kinetic fluorescence aniso-
tropy based method for inhibitor testing is highly desirable because
efficient inhibitors frequently have fluorescence properties, but this
does not influence the detected anisotropy change significantly.
During the last few years, we have made some effort to disconnect
the isopeptidase and transamidase activities of transglutaminases. In
the case of TG2, mutation of W278F and W332F residues, which par-
ticipate in the formation of the substrate-binding cleft and active site,
resulted in mutants which prefer transamidase or isopeptidase activity,
respectively. The problem is that these mutants express their special
property only on small substrates. When their activities were measured
using the developed protein-peptide based assay, this property dis-
appeared. The TG2 W332F mutant possessed lower isopeptidase ac-
tivity than the wild type, and the TG2 W278F mutant showed higher
isopeptidase activity than the TG2 W332F mutant with the FLpepT26-
S100A4(GST) substrate [12].
The disconnection of isopeptidase and cross-linking activities in a
FXIII-A mutant, which can cleave isopeptide bond with high reaction
speed and does not crosslink proteins, could have therapeutic im-
portance, because it could enhance the release of α2-antiplasmin from
the blood clot and cleave isopeptide bonds between fibrin molecules
contributing to destabilization, fibrinolysis and consequent elimination
of unwanted blood clots. Based on the structural homology between
TG2 and FXIII-A, in an attempt to increase the substrate-binding in the
active site cleft of the enzyme, we made W316F and W371F mutant
FXIII-A proteins (corresponding to the W278F and W332F in TG2
proteins, respectively). But, FXIII-A W371F was completely inactive,
and FXIII-A W316F possessed low transamidase and isopeptidase ac-
tivities (both in small peptide- and protein-based assays; data not
shown).
4. Conclusions
In vivo most of the transglutaminase catalyzed reactions act on
proteins, but the in vitro assays generally use peptides or small mole-
cules as substrates, often due to economic reasons. In addition, activity
assays measuring absorbance in the UV region or fluorescence are fre-
quently not applicable to test transglutaminase activity in biological
samples. This makes it difficult to obtain relevant conclusions when
regulatory ligands and inhibitors are tested as possible therapeutic
transglutaminase agents. FXIII-A has an emerging therapeutic potential
to cure thrombotic diseases, preventing the stabilization of unwanted
blood clots. The methods developed in the present study provide tools
to generate reliable and relevant results concerning the effect of de-
veloped regulatory molecules. Following the anisotropy changes during
crosslinking or isopeptide cleavage offers a relatively sensitive and
easily measurable method to monitor FXIII-A transglutaminase and
isopeptidase activities on protein substrates. Moreover, our system,
combining the application of the same substrates to test opposite di-
rections of transglutaminase catalyzed reactions decreases the draw-
backs generated by the different binding properties of various applied
substrates in the thus far developed assays in the field.
Another important issue is the presence of various transglutami-
nases and their reactions in living systems. The present assay system
provides the basis for monitoring both directions of transglutaminase
reactions in complex, homogeneous biological samples and for high-
throughput screening of effectors and mutant transglutaminases. Our
long term vision is to produce appropriate assays for the development
of non-immunogenic transglutaminase mutants or abzymes which are
able to cleave isopeptide bonds and can reverse progressive, deadly,
non-curable diseases such as various types of fibrosis and thrombotic
diseases.
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